 NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG FSE Prime Standard: VSC, today announced the signing of an agreement under which Immunic will settle its remaining obligation of a 4.4 royalty on net sales of selective oral DHODH inhibitor, IMU-838, for 17.25 million. The transaction will be payable 50 in cash and 50 in shares of Immunics common stock. 